Aquestive Therapeutics (AQST) PT Raised to $8 at Lake Street Capital Markets
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/25/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mailGet Alerts AQST Hot Sheet
Price: $4.00 -3.15%
Rating Summary:
12 Buy, 0 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 14 | New: 15
Rating Summary:
12 Buy, 0 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 14 | New: 15
Join SI Premium – FREE
(Updated - March 7, 2024 12:32 PM EST)
Lake Street Capital Markets analyst Thomas Flaten raised the price target on Aquestive Therapeutics (NASDAQ: AQST) to $8.00 (from $3.00) while maintaining a Buy rating.
The analsyt commented, "The stage is set for an eventful 2024 with Libervant’s potential April FDA approval and Anaphylm's anticipated NDA submission by year-end, both substantial value generating events. Yesterday, the Company reported 4Q24 revenues of $13.2M, which exceeded our estimate of $11.8M. Affirm Buy and raising PT to $8."
You May Also Be Interested In
- Freedom Broker Upgrades Goldman Sachs (GS) to Buy
- Lockheed Martin (LMT) PT Raised to $692 at UBS
- FirstService Corp (FSV) PT Lowered to $179 at BMO Capital
Create E-mail Alert Related Categories
Analyst Comments, Analyst PT ChangeRelated Entities
FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
